Aktuella utlysningar, vecka 17, 2019
Grants Office tipsar om aktuella utlysningar
Svenska och nordiska utysningar
Utlysning FoU-program: Att leva och arbeta med psykisk ohälsa – AFA Försäkring
Psykiska diagnoser utgör den näst vanligaste orsaken till långtidssjukskrivning bland de som arbetar inom privat sektor. AFA Försäkring stödjer forskning och utveckling inom arbetsmiljö och hälsa med 150 miljoner kronor per år. Det övergripande syftet är att minska de långvariga sjukskrivningarna och förebygga arbetsskador. Relevans, vetenskaplig kvalitet och förväntad praktisk nytta är viktiga kriterier när vi bedömer vilka projekt som ska få anslag. Nu satsar AFA Försäkring på uppdrag av arbetsmarknadens parter – Svenskt Näringsliv och LO – 40 miljoner kronor på FoU-programmet Att leva och arbeta med psykisk ohälsa. Syftet med detta program är att minska sjukfrånvaron på grund av psykisk ohälsa hos arbetare i privat sektor.
Closing date: 7 May 2019
Stipendium för forskning utomlands – Hjärt-Lungfonden
Hjärt-Lungfonden beviljar ett begränsat antal stipendier för forskning vid erkänd utländsk institution. Dessa stipendier tilldelas företrädesvis disputerade forskare för perioder om 6-12 månader upp till högst tre år. Stipendierna riktar sig främst till de som är postdok.
Closing date: 14 May 2019
Agricultural and medical research grants – Ekhaga Foundation
Within Medicine the foundation supports research relating to the improvement and further development of such methods of healing that are natural and suited to promote the inherent human ability of self-healing. The holistic view of the human health, where not only medicine but also the effects of food and environment are observed, is here of great importance. Research in the significance of the environment and the way of life for the state of health is also supported. Furthermore, the foundation is open for contributing to the creation of a research center in Sweden for biological medicine.
Closing date: 20 May 2019
Postdoc-stöd – AFA Försäkring
AFA Försäkring utlyser ett postdoc-stöd på 2 miljoner kronor inom området hälsa. Årets stöd riktar sig till dig som forskar inom rehabilitering och återgång i arbete.
Closing date: 17 June 2019
Research fellowships - European Society for Medical Oncology
The European Society for Medical Oncology invites applications for its research fellowships. These support high-quality research projects in either translational or clinical research. Fellowships may be in the following areas: •translational – aiming to provide training in translational research in European centres and improve career development through collaboration; •clinical – aiming to provide training in clinical research in European cancer centres, as well as to support the development of clinical oncology research projects.
Closing date: 15 May 2019
Kemali international prize - International Brain Research Organization
The International Brain Research Organization, via the IBRO Dargut and Milena Kemali Foundation, invites nominations for the Kemali international prize. This recognises a scientist’s contributions to basic or clinical neuroscience. Scientists who were under the age of 45 on 31 December 2018 may be nominated.
Closing date: 15 May 2019
EFSD/Boehringer Ingelheim European research programme - European Association for the Study of Diabetes
The European Foundation for the Study of Diabetes and Boehringer Ingelheim invite applications for their European research programme. This aims to stimulate and accelerate basic or clinical research on the inter-organ crosstalk and related pathophysiology in diabetes and its complications. Applications are invited from single, or groups of non-profit institutions in Europe and associated countries. The principal investigator and any co-investigators must be employed full-time at a non-profit institution, and the study must be conducted at their place of work.
Closing date: 1 Aug 2019
Awards for innovating and inspiring science - Nature
Nature, in collaboration with The Estée Lauder Companies, invites applications for its awards for innovating and inspiring science. These recognise female scientists and those involved in projects encouraging women to become more engaged in STEM subjects. The following awards are available: inspiring science award and innovating science award.
Closing date: 6 May 2019
Clinical research awards - European Society of Cataract and Refractive Surgeons
The European Society of Cataract and Refractive Surgeons invites applications for its clinical research awards. These support independent clinical research in the field of cataract and refractive surgery. Proposals may include clinical research into the use of specific medical treatments and surgeries, clinical research on the pharmaco-economic analysis of particular treatments, or research into the optimal management of national and global health care systems in ophthalmology.
Closing date: 31 May 2019
Prostate Cancer Research Program (PCRP): DOD
The Department of Defense, under its prostate cancer research programme, invites pre-applications for its idea development award, Early Investigator Research Award, and Physician Research Award. This supports research that will lead to the elimination of death from prostate cancer and enhance the well-being of those suffering from the disease and their families. Applications must address one or more of the following challenges:
•improve the quality of life for survivors of prostate cancer;
•develop treatments that improve outcomes for men with lethal prostate cancer;
•reduce lethal prostate cancer in African Americans, veterans and other high-risk populations;
•define the biology of lethal prostate cancer to reduce death.
Idea Development Award (LOI: June 6, 2019 5:00 p.m. Eastern Time (ET), Full Application: September 19, 2019 11:59 p.m. ET);
Early Investigator Research Award (LOI: June 6, 2019 5:00 p.m. ET, Confidential Letters of Recommendation: July 2, 2019 5:00 p.m. ET, Full Application: June 27, 2019 11:59 p.m. ET);
Physician Research Award (LOI: June 6, 2019 5:00 p.m. ET, Confidential Letters of Recommendation: July 2, 2019 5:00 p.m. ET, Full Application: June 27, 2019 11:59 p.m. ET).
Funding Opportunity Announcement (FOA): Idea Development Award (W81XWH-19-PCRP-IDA); Early Investigator Research Award (W81XWH-19-PCRP-EIRA); Physician Research Award (W81XWH-19-PCRP-PRA).
Innovative basic research on adducts in cancer risk identification and prevention (R01 & R21): NIH
The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks.
In well-justified cases, innovative studies using the adductomic approaches in the context of cancer etiology and/or gene-environment interaction research may also be appropriate. For projects intended for NIEHS support, the focus may be on innovative technology and method development.
Deadlines: July 2, 2019; November 6, 2019; July 2, 2020; November 6, 2020; July 8, 2021; November 8, 2021, by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-19-251 (R01), PAR-19-252 (R21)
Innovation for HIV Vaccine Discovery (R01): NIH
The purpose of this Funding Opportunity Announcement (FOA) is to support high risk, high impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. In keeping with the high risk, high impact nature of this research, this FOA supports a Go/No-Go approach to funding high risk research, which is significantly different from most R01 projects. Continued funding for the full award duration is dependent upon achieving negotiated “Go/No-Go” criteria by the end of Year 2.
Deadlines: August 1, 2019, by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-17-263
Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01): NIH
The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS). These PQs are not intended to represent the full range of NCI's priorities in HIV/AIDS-related cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems and paradoxes in key areas of AIDS-related cancer research that are deemed important but have not received sufficient attention.
Provocative Questions in Cancer with an Underlying HIV Infection involves a set of 6 PQs.
Each application must address one and only one specific PQ from the list below, exactly as defined in this FOA.
PQ1. Other than immune dysfunction (including inflammation) and known oncogenic mechanisms or risk factors that affect PLWA, by what other mechanism(s) does HIV infection promote the development or progression of tumors either directly or indirectly in patients with treated HIV infection?
PQ2. What if any are the contributions of transposable elements or endogenous retroviruses to cancer development in PLWH, and what role does HIV play in their mobilization across the genome?
PQ 3. Other than direct effects of HIV infection, what are the factors that contribute to the poorer survival of PLWH with cancer when compared to HIV-uninfected patients with the same tumor type? How can this knowledge inform improvements in cancer care in patients with HIV and cancer?
PQ 4. What are the determinants of the size and diversity of reservoirs of oncogenic agents that impact the development of malignancies in PLWH?
PQ 5. How does the biology of aging affect the development of cancer in PLWH?
PQ 6. Can novel in vitro and in vivo models of HIV/AIDS-associated malignancies be developed to study their development, pathogenesis, and the potential evaluation of novel treatments for common HIV/AIDS-associated malignancies?
Deadlines: August 1, 2019; August 3, 2020, by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-CA-19-032
Inter-organelle Communication in Cancer (R01): NIH
The purpose of this Funding Opportunity Announcement (FOA) is to support research projects that examine how inter-organelle communication in cancer cells and/or tumor-associated cells affects cellular function, adaptation, and phenotypic plasticity.
NEUROIMAGING AND CSF BIOMARKER DEVELOPMENT PROGRAM, Alzheimer's Drug Discovery Foundation, US
This RFP seeks to support the development of Cerebrospinal fluid (CSF) biomarkers and neuroimaging biomarkers for multiple contexts of use (see below) that include but are not limited to:
1. Clearly demonstrate target engagement for novel therapeutics: The development of biomarkers that can serve as measures of target engagement for novel targets such as neuroinflammation features. High priority will be given to projects developing biomarkers that can be used in combination with therapies currently in development and serve as companion biomarkers.
2. Detect signs of disease earlier and monitor progression: Developing sensitive biomarkers that can detect disease earlier than currently available tests.
3. More accurately diagnose and distinguish between dementia subtypes: Biomarkers that can distinguish between subtypes and stratify patients in clinical trials are of high priority.
Deadlines: July 12, 2019 (Letter of Intent), August 9, 2019 (Invited Full Proposal)
PROGRAM TO ACCELERATE CLINICAL TRIALS (PACT), Alzheimer's Drug Discovery Foundation, US
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer's disease and related dementias. The PACT RFP supports clinical trials, experimental medicine, and regulatory studies for novel drugs (small molecules and biologics including antibodies, peptides, gene therapies), repurposed drugs (existing drugs that are approved for other diseases and conditions), repositioned drugs (existing drugs that have entered clinical trials for other indications and have not yet been approved), and natural products. Specifically, the PACT RFP supports: 1. Early-stage human clinical trials, 2. Regulatory studies.
Deadlines: July 12, 2019 (Letter of Intent), August 9, 2019 (Invited Full Proposal)